Author(s)

Farel Elilie Mawa Ongoth^1,2*, Rudel Godrèche Kondo³, Philestine Clausina Mikolélé Ahoui Apendi^2,3, Nestor Ghislain Andzouana Mbamognoua^1,2, Raïssa Laure Mayanda Ohouana^1,2, Aymande Okoumou-Moko¹, Ornella Marline Yvonne Dinghat¹, Joël Rudy Ekoundzola¹, Sévérin Nkoua Eloi¹, Régis Moyikoua^2,4, Arnaud Mongo Onkouo^2,3, Blaise Irénée Atipo Ibara^2,3

¹Department of Metabolic and Endocrine Diseases, University Hospital of Brazzaville, Brazzaville, Republic of Congo.
²Faculty of Health Sciences, Marien NGOUABI University, Brazzaville, Republic of Congo.
³Department of Gastroenterology, University Hospital of Brazzaville, Brazzaville, Republic of Congo.
⁴Medical Imaging Department, University Hospital of Brazzaville, Brazzaville, Republic of Congo.

Introduction: Introduction: Type 2 diabetes mellitus is a factor in the initiation and progression of metabolic dysfunction-associated steatotic liver disease (MASLD) to its severe forms with hepatic fibrosis, with a risk of progression to cirrhosis and hepatocellular carcinoma. Hepatic fibrosis has prognostic value in patients with type 2 diabetes mellitus and MASLD. The aim of this study was to investigate the risk factors for hepatic fibrosis in subjects with type 2 diabetes and MASLD in Brazzaville. Patients and Methods: Cross-sectional study and analysis were conducted over 11 months at Brazzaville University Hospital and SUZA Clinic, including patients with type 2 diabetes and MASLD who underwent non-invasive evaluation of liver fibrosis by elastometry or Fibroscan®. Results: The study included 120 patients with a median age of 56 years (50.64), with a clear female predominance. The mean duration of diabetes mellitus was 6.1 ± 5 years. Patients were treated with oral antidiabetics (53.3%) and had a mean glycated hemoglobin of 8.75 ± 1.47%. Liver fibrosis was present in 52 patients (43.3%). Advanced fibrosis was present in 32.6% of cases. Hepatic fibrosis was significantly associated with metabolic syndrome (p = 0.000), severe steatosis (p = 0.012), chronic complications of diabetes mellitus (p = 0.04), dyslipidemia (p = 0.000), and insulin therapy (p = 0.0013). Conclusion: Hepatic fibrosis is common in patients with type 2 diabetes mellitus and MASLD. Its presence is statistically significantly related to metabolic syndrome, dyslipidemia, severe steatosis, insulin therapy, and chronic complications of diabetes mellitus.

Type 2 Diabetes Mellitus, Metabolic Dysfunction-Associated Steatotic Liver Disease, Advanced Fibrosis, Brazzaville

Ongoth, F. , Kondo, R. , Apendi, P. , Mbamognoua, N. , Ohouana, R. , Okoumou-Moko, A. , Dinghat, O. , Ekoundzola, J. , Eloi, S. , Moyikoua, R. , Onkouo, A. and Ibara, B. (2025) Risk Factors for Liver Fibrosis in Patients with Type 2 Diabetes Mellitus and Metabolic Dysfunction–Associated Steatotic Liver Disease in Brazzaville. Open Journal of Endocrine and Metabolic Diseases, 15, 142-153. doi: 10.4236/ojemd.2025.158014.